TechConnect Innovation Program

LIGHT: Immunotherapy for treatment of primary tumors and metastatic disease

University of Chicago, IL, United States

TECHNOLOGY SUMMARY

LIGHT is a multi‐pronged immunotherapeutic approach for the treatment of cancer. LIGHT supercharges an anti‐tumor immune response by recruiting immune cells to tumor sites and by stimulating T cell activation. LIGHT therapy destroys distant metastases and creates immune memory, blocking cancer recurrence.

Primary Application Area: Biotech & Biological Sciences

Technology Development Status: Concept

Technology Readiness Level: TRL 3

FIGURES OF MERIT

Value Proposition: LIGHT is a platform immuno-oncology therapeutic opportunity. Early studies suggest that LIGHT may be effective in patient subsets where current immunotherapies (CTLA4 and PD1) are not, because of its immune-cell recruiting mechanism of action.

SHOWCASE SUMMARY

Organization Type: Academic/Gov Lab

National Innovation Awardee

Showcase Booth #: 637

Website: www.uchicago.edu

GOVT/EXTERNAL FUNDING SOURCES

Government Funding/Support to Date:

Primary Sources of Funding: Federal Grant

Looking for: Development / License Partners